MENU CONTENTS

PNEUMOSTEM

Preventative Treatment of Bronchopulmonary Dysplasia (BPD)PNEUMOSTEM®

뉴모스템

PNEUMOSTEM® is under-development for the preventive treatment of Bronchopulmonary Dysplasia (BPD) for premature infants. It is based on Allogeneic Umbilical Cord Blood-derived Mesenchymal Stem Cells.


PNEUMOSTEM® successfully completed Phase 2 clinical trial in Korea and its administration in Phase 1/2 (FDA IND) clinical trial in the U.S. Orphan Drug Designation was granted in the U.S. and E.U.

Further researches for expanding indications to the various adult lung diseases are also in progress
Product Name
PNEUMOSTEM®
Manufacturer
MEDIPOST
Indication
Preventative treatment of Bronchopulmonary Dysplasia (BPD)
Administration
Administration in airway
Before and After
PNEUMOSTEM®
(Animal experiments):

손상된 폐 Damaged lung

투여 5일 후 폐 5 Days After

상단으로